Earlier this week, the American Civil Liberties Union and several other groups filed suit against Myriad Genetics -- the company that holds the patent on the breast cancer gene. They're hoping to get the breast cancer gene patent revoked, but more than that, they're aiming to stop gene patenting all together.
Today, in my new column in Slate's Double X Magazine, I go into the story of the breast cancer gene and the impact the ACLU claims it's had on science and patient care (a hint: it's not good). I also look at the suit itself, the cases that have come before this one, and what they say…
Advertisment
